Loading
The analysis that showed HPV-positive throat cancers are a different, far more curable disease, launching two decades of de-escalation research.
Ang et al., NEJM 2010: 3-year OS 82.4% for HPV-positive vs 57.1% for HPV-negative oropharyngeal cancer; HPV status was the strongest prognostic factor, with tobacco exposure modifying it. Led to a separate AJCC staging system for HPV-positive disease (8th edition) and the de-escalation trials that followed.
Numbers are from the trial as recorded here; see the source links in the table below. This is orientation, not medical advice: ask your team how closely the trial population matches you.
743 enrolled.
| Endpoint | Arm | n | Value | HR (95% CI) | p | Source |
|---|---|---|---|---|---|---|
| Overall survival at 3 years by HPV status | HPV-positive | - | 82.4% | - | - | link |
| HPV-negative | - | 57.1% |
Shares HPV-positive (p16) head and neck cancer, HPV-positive oropharyngeal cancer, Head and neck squamous cell carcinoma, IMRT / IGRT (modern external beam).
Shares HPV-positive (p16) head and neck cancer, HPV-positive oropharyngeal cancer, Head and neck squamous cell carcinoma, IMRT / IGRT (modern external beam).
Shares HPV-positive (p16) head and neck cancer, HPV-positive oropharyngeal cancer, NRG Oncology, Head and neck squamous cell carcinoma.
Shares HPV-positive oropharyngeal cancer, NRG Oncology, Head and neck squamous cell carcinoma, IMRT / IGRT (modern external beam).
Shares HPV-positive (p16) head and neck cancer, HPV-positive oropharyngeal cancer, IMRT / IGRT (modern external beam).
Shares HPV-positive oropharyngeal cancer, HPV & HBV vaccination, Head and neck squamous cell carcinoma.
Shares HPV-positive oropharyngeal cancer, Head and neck squamous cell carcinoma.
Shares HPV-positive (p16) head and neck cancer, HPV-positive oropharyngeal cancer, IMRT / IGRT (modern external beam).